1[1]Poullis A, Foster R, Nortlfield TC, et al. Fecal markers in the assessment of activity in inflammatory bowel disease. Aliment Pharmacol Ther, 2002,16:675.
2[2]Becker K, Berger M, Niederau C, et al. Individual fecal α 1-amtitrypsm excretion reflects clinical activity in Crohn' s disease but not in ulcerative colitis. Helpato Gastroenterlogy, 1999,46:2309.
3[3]Becker K, Niederau C, Frieling T Faecal excretion of alpha2-maeroglobulin: a novel marker for disease activity in patients with inflammatory bowel disease. Z Gastroemerol, 1999,37(7) :597.
4[4]Fine KD, Ogunji F, George J, et al. Utility of a rapid fecal latex agglutination test detecting the neutrophil protein, lactoferrin, for diagnosing inflammatory causes of chronic diarrhea. Am J Gastroenterol, 1998,93 (8):1300.
5[5]Sugi K, Saitoh O, Hirata I, et al. Fecal laetoferrin as a marker for disease activity in inflananatory bowel disease: comparison with other nentrophil-derived proteins. Am J Gastroenterol, 1996,91 (5): 927.
6[6]Sangfelt P, Carlson M, Thom M, et al. Neutrophil and eosinophil granule proteins as markers of response to local prednisolone treatment in distal ulcerative colitis and proetitis. Am J Gaatroentero1,2001,96 {4): 1085.
7[7]Handy LM, Ghosh S, Ferguson A. Investigation of neutrophils in the gut lumen by assay of ganulocyte elastase in whole-gut lavage fluid. Scand J Gastroenterol 1996,31:700.
8[8]Kayazawa M, Saitoh O, Kojima K, et al. Laetofenin in whole gut lavage fluid as a marker for disease activity in inflammatory bowel disease: comparison with other netrophil derived proteins. Am J Gastroenterol, 2002,97:360.
9[9]Peterson CGB, Ekland E, Taha Y, et al. A new method for the quantification of neutrophil and eosinophil cationic proteins in feces: Establishment of normal levels and clinical application in patients with inflammatory bowel disease. Am J Gastroentero1,2002,97(7): 1755.
10[10]Nielsen HO, Gionchetti P, Ainsworth M, et al. Rectal dialysate and fecal concentrations of nentrophil gelatinase-associated lipocalin, interleukin-8and tumor necrosis factor-α in ulcerative colitis. Am J Gastroceterol, 1999,94(10) :2923.
2Schoepfer AM, Beglinger C, Straumann A,et al. Fecal calprotect- incorrelates more closely with the simple endoscopic score for Crohn' sdisease (SES-CD) than CRP, blood leukocytes, and the CDAI[J]. Am J Gastroenterol,2010,105(1): 162-169.
3Tibble JA, Sigthorsson G, Bridger S, etal. Surrogate markers of intestinalinflammation are predictive of relapse in patients with in- flammatory bowel disease [J]. Gastroenterology, 2000, 119 ( 1 ) : 15.
4Limburg PJ, Ahlquist DA, Sandbom WJ, et al. Fecal calprotec- tin levelsprediet colorectal inflammation among patients with chronic diarrhoea re-ferred for colonoscopy[J]. Am J Gastroente- rol, 2002,95 (10) : 2831.
5Sangfelt P, Carlson M, ThomM, et el. N eutrophil and eosinophil granuleproteins as markers of response to local prednisolone treat- ment in distal ulcerative colitis and proetitis[J]. Am J Gaatroente rol,2001,96(4) :1085.
6PoullisA, Foster R, NorthfieldTC, et al. Fecal markers in the assessmentof activity in inflammatory bowel disease[J]. Aliment Pharmacol Ther, 2002,16 : 675-681.
8Sehohnerieh J, Warren B. Diferential diagnosisand other forms of in-flammatory bowel disease[M]//Satsangi J, Suthedand LR, eds. Inflammatory bowel diseases. Spain: Elsevier, 2003: 199- 217.
9Simren M, Axelsson J, Gillberg R, et al. Quality of life in in flammatorybowel disease in remission: the impact of IBS-like symptoms and associated psychological factors[J]. Am J Gastro- enterol, 2002,97 : 389-396.
10Langhorst J, Elsenbruch S, Koelzer J, et al. Noninvasivemark- ers in the assessment of intestinal inflammation in inflam-matory bowel diseases: Performance of fecal laetoferrin, calpro-tectin, and PMN elastas'e, CRP, and clinical indices[J]. Am J Gastro- enterol, 2008,103 : 162-169.
